amgen

It's great when a biotech company can deliver on a promising drug. Although Amgen Inc. (AMGN) reported disappointing earnings in the first quarter, many investors put their hopes up on its experimental denosumab bone drug for treating post-menopausal osteoporosis. This drug, which was filed for...